Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1426 to 1440 of 2188 results for guidelines

  1. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    10 August 2021

  2. What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    17 December 2021

  3. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (HTG316)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.

    HealthTech guidance
    Published
    14 August 2013
    View recommendations

    Sections for HTG316

  4. Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of systemic anticancer treatments Number NG161

    Research recommendation
    Published
    21 October 2021

  5. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  6. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    14 July 2022

  7. Geriatric assessment and care:- What is the cost-effectiveness of comprehensive geriatric assessment and care on specialist units compared with alternative models of care on general wards?

    from the US) and evidence from the economic analysis carried out for this guideline suggest that care in a specialist unit is likely to...

    Research recommendation
    Published
    29 January 2016

  8. Relaxation and biofeedback:- What is the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related outcomes?

    not sufficient to make recommendations. Patient representation in the Guideline Development Group supports this view, from a personal...

    Research recommendation
    Published
    9 June 2015

  9. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    Any explanatory notes(if applicable) Why this is important: This guideline has established that atorvastatin 20 mg is clinically and...

    Research recommendation
    Published
    9 June 2015

  10. Using mental capacity assessment tools to assess capacity:- What is the accuracy and/or effectiveness, cost effectiveness and acceptability of mental capacity assessment tools that are compliant with the Mental Capacity Act 2005?

    mental capacity as outlined in the Mental Capacity Act 2005. Although the guideline committee reviewed some evidence evaluating the...

    Research recommendation
    Published
    18 December 2018

  11. Natural history of varicose veins:- In people with varicose veins at CEAP (Clinical, etiological, anatomical and pathophysiological) stage C2 or C3, what are the factors that influence progression of the disease to CEAP stages C5 or C6?

    notes(if applicable) Why this is important:- The evidence review for the guideline showed a lack of high-quality evidence on the...

    Research recommendation
    Published
    9 June 2015

  12. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729

  13. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

    HealthTech guidance
    Published
    17 April 2025
    View recommendations

    Sections for HTG742

  14. Imaging options in occult hip fracture: In people with a continuing suspicion of a hip fracture but whose radiographs are normal, what is the clinical and cost effectiveness of CT compared with MRI, in confirming or excluding the fracture?

    Any explanatory notes(if applicable) Why this is important:The Guideline Development Group's consensus decision to recommend CT over a...

    Research recommendation
    Published
    3 February 2023

  15. Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with a cholinesterase inhibitor and memantine for people with Parkinson's disease dementia if treatment with a cholinesterase inhibitor alone is not effective or no longer effective?

    Any explanatory notes(if applicable) Why this is important:- The guideline committee felt that cholinesterase inhibitors, memantine and...

    Research recommendation
    Published
    15 October 2018